DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 21-748

Keller and Heckman
Attention: John Dubeck
Agent for Biovail Laboratories Incorporated
1001 G. Street, N.W., Suite 500 West
Washington, DC 20001

Dear Mr. Dubeck:

Please refer to your new drug application (NDA) dated April 27, 2004, received April 27, 2004, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Glumetza™ (metformin hydrochloride extended-release tablets), 500 mg and 1000 mg.

We acknowledge receipt of your submissions dated March 9, and April 6, and June 1, 2005.

The April 6, 2005, submission constituted a complete response to our February 25, 2005, action letter.

This new drug application provides for the use of Glumetza™ (metformin hydrochloride extended-release tablets) as monotherapy as an adjunct to diet and exercise to improve glycemic control in adult patients (18 years and older) with type 2 diabetes. Glumetza may be used concomitantly with a sulfonylurea or insulin to improve glycemic control in adults.

We completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text.

The final printed labeling (FPL) must be identical to the enclosed labeling (package insert submitted on February 25, 2005, patient package insert submitted on February 25, 2005, carton labels submitted on April 27, 2004, and container bottle labels submitted on February 4, and 15, 2005). Marketing the product with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format – NDAs*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved NDA 21-748**." Approval of this submission by FDA is not required before the labeling is used."

The agreed upon dissolution method and specifications for the 500 mg and 1000 mg tablets are as follows:

Apparatus type	USP Apparatus-1 ((b)(4))
Medium	(b)(4)
Temperature of medium	37°C
Speed of rotation	(b)(4)
Specification	2 hr: (b)(4) , 4 hr: (b)(4) , 12 hr: NLT (b)(4)

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for children less than 10 years of age and deferring pediatric studies for ages 10 to 17 years of age for this application.

Your deferred pediatric studies required under section 2 of the Pediatric Research Equity Act (PREA) are considered required postmarketing study commitments. The status of this postmarketing studies shall be reported annually according to 21 CFR 314.81. This commitment is listed below.

1. Deferred pediatric study under PREA for the treatment of glycemic control in pediatric patients ages 10 to 17.

2. Final Report Submission: December 31, 2007.

Submit final study reports to this NDA. For administrative purposes, all submissions related to this/these pediatric postmarketing study commitments must be clearly designated "**Required Pediatric Study Commitments**".

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising,
and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Ms. Jena Weber, Regulatory Health Project Manager at 301-827-6422.

Sincerely,

{See appended electronic signature page}

David G. Orloff, M.D.
Director
Division of Metabolic and Endocrine Drug Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

Enclosures: (package insert, patient package insert, immediate container labels, carton labels)

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

David Orloff

6/3/05 10:40:29 AM